Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety.
Ana OakninAmit M OzaDomenica LorussoCarol AghajanianAndrew DeanNicoletta ColomboJohanne I WeberpalsAndrew R ClampGiovanni ScambiaAlexandra LearyRobert W HollowayMargarita Amenedo GancedoPeter C FongJeffrey C GohDavid M O'MalleyDeborah K ArmstrongSusana BanerjeeJesus García-DonasElizabeth M SwisherTerri CameronLara MaloneySandra GobleJonathan A LedermannRobert L ColemanPublished in: Cancer medicine (2021)
Rucaparib maintenance treatment provided clinically meaningful efficacy benefits across subgroups based on response to last platinum-based chemotherapy or baseline disease.
Keyphrases